Aethlon Medical Files Q3 2025 10-Q

TL;DR

AETH filed its Q3 10-Q, check financials for the period ending Dec 31, 2024.

AI Summary

Aethlon Medical, Inc. filed its 10-Q for the period ending December 31, 2024. The company, incorporated in Nevada and headquartered in San Diego, CA, operates in the Surgical & Medical Instruments & Apparatus sector. This filing covers the third quarter of their fiscal year, which ends on March 31, 2025. The filing was made on February 12, 2025.

Why It Matters

This filing provides investors with an update on Aethlon Medical's financial performance and operational status for the third quarter of their fiscal year, offering insights into their current financial health.

Risk Assessment

Risk Level: medium — As a medical device company, Aethlon Medical is subject to regulatory risks, clinical trial outcomes, and market adoption challenges, which can significantly impact its financial performance.

Key Players & Entities

• Aethlon Medical, Inc. (company) — Filer of the 10-Q
• 0000882291 (company) — Central Index Key for Aethlon Medical Inc.
• 3841 (company) — Standard Industrial Classification Code for Surgical & Medical Instruments & Apparatus
• 133632859 (company) — IRS Number for Aethlon Medical Inc.
• NV (company) — State of Incorporation for Aethlon Medical Inc.
• 11555 SORRENTO VALLEY ROAD, SUITE 203 (company) — Business and Mail Address for Aethlon Medical Inc.
• SAN DIEGO (company) — City for Business and Mail Address
• CA (company) — State for Business and Mail Address
• 92121 (company) — ZIP Code for Business and Mail Address
• 619-941-0360 (company) — Business Phone Number for Aethlon Medical Inc.

FAQ

Key Financial Figures

• $0.001 — t: TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAM

Filing Documents

• aethlon_i10q-123124.htm (10-Q) — 658KB
• aethlon_10q-ex3101.htm (EX-31.1) — 9KB
• aethlon_10q-ex3201.htm (EX-32.1) — 5KB
• 0001683168-25-000960.txt ( ) — 3777KB
• aemd-20241231.xsd (EX-101.SCH) — 31KB
• aemd-20241231_cal.xml (EX-101.CAL) — 36KB
• aemd-20241231_def.xml (EX-101.DEF) — 142KB
• aemd-20241231_lab.xml (EX-101.LAB) — 284KB
• aemd-20241231_pre.xml (EX-101.PRE) — 246KB
• aethlon_i10q-123124_htm.xml (XML) — 456KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 4 CONDENSED CONSOLIDATED BALANCE SHEETS AT DECEMBER 31, 2024 (UNAUDITED) AND MARCH 31, 2024 4 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2024 AND 2023 (UNAUDITED) 5 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2024 AND 2023 (UNAUDITED) 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED DECEMBER 31, 2024 AND 2023 (UNAUDITED) 7 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 8 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 26 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 27 PART II. OTHER INFORMATION 28 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 28 ITEM 1A.

RISK FACTORS

RISK FACTORS 28 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 29 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 29 ITEM 4. MINE SAFETY DISCLOSURES 29 ITEM 5. OTHER INFORMATION 29 ITEM 6. EXHIBITS 30

SIGNATURES

SIGNATURES 31 2 CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the safe harbor created by those sections. We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Quarterly Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of our clinical trials, our capital outlook, successful completion of our clinical trials, our ability to raise additional capital, our ability to maintain our Nasdaq listing, U.S. Food and Drug Administration ("FDA") approval of our products candidates, our ability to comply with changing government regulations, patent protection of our proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with the Securities and Exchange Commission (the "SEC"). Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and ot

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2024 March 31, 2024 (Unaudited) ASSETS Current Assets Cash and cash equivalents $ 4,825,387 $ 5,441,978 Deferred offering costs 54,750 277,827 Prepaid expenses and other current assets 88,270 505,983 Total current assets 4,968,407 6,225,788 Property and equipment, net 762,138 1,015,229 Operating lease right-of-use asset 673,315 883,054 Patents, net 688 1,100 Restricted cash 87,506 87,506 Deposits 33,305 33,305 Total assets $ 6,525,359 $ 8,245,982 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 610,909 $ 777,862 Due to related parties 781,899 546,434 Operating lease liability, current portion 307,326 290,565 Accrued professional fees 73,537 215,038 Total current liabilities 1,773,671 1,829,899 Operating lease liability, less current portion 417,522 649,751 Total liabilities 2,191,193 2,479,650 See Commitments and Contingencies Note 9 – Stockholders' Equity Common stock, par value $ 0.001 per share; 60,000,000 shares authorized as of December 31, 2024 and March 31, 2024; 13,986,669 and 2,629,725 shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively 13,987 2,629 Additional paid-in capital 166,037,129 160,337,371 Accumulated other comprehensive loss ( 17,026 ) ( 6,940 ) Accumulated deficit ( 161,699,924 ) ( 154,566,728 ) Total stockholders' equity 4,334,166 5,766,332 Total liabilities and stockholders' equity $ 6,525,359 $ 8,245,982 The accompanying notes are an integral part of these condensed consolidated financial statements . 4 AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Three and Nine Month Periods Ended December 31, 2024 and 2023 (Unaudited) Three Months Ended December 31,

View Full Filing

View this 10-Q filing on SEC EDGAR